The Goldman Sachs Group Issues Pessimistic Forecast for Silence Therapeutics (NASDAQ:SLN) Stock Price

Silence Therapeutics (NASDAQ:SLN) had its target price lowered by stock analysts at The Goldman Sachs Group from $6.00 to $4.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “sell” rating on the stock. The Goldman Sachs Group’s target price points to a potential downside of 15.43% from the company’s previous close.

Other research analysts have also recently issued reports about the stock. Chardan Capital reaffirmed a “buy” rating and set a $55.00 price target on shares of Silence Therapeutics in a research report on Tuesday, December 10th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price target on shares of Silence Therapeutics in a research report on Wednesday, January 29th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, December 2nd. Finally, William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $40.67.

Silence Therapeutics Stock Performance

Silence Therapeutics stock opened at $4.73 on Tuesday. Silence Therapeutics has a 1 year low of $4.06 and a 1 year high of $27.72. The firm has a 50 day moving average price of $5.49 and a 200 day moving average price of $11.53. The company has a market cap of $141.57 million, a price-to-earnings ratio of -3.01 and a beta of 1.05.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SLN. Nantahala Capital Management LLC lifted its position in shares of Silence Therapeutics by 424.8% in the 4th quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company’s stock worth $7,222,000 after buying an additional 849,676 shares during the last quarter. Eventide Asset Management LLC bought a new position in shares of Silence Therapeutics in the 3rd quarter worth about $11,635,000. Redmile Group LLC lifted its position in shares of Silence Therapeutics by 26.3% in the 4th quarter. Redmile Group LLC now owns 2,399,317 shares of the company’s stock worth $16,507,000 after buying an additional 500,000 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Silence Therapeutics by 48,165.6% in the 4th quarter. Bank of America Corp DE now owns 499,066 shares of the company’s stock worth $3,434,000 after acquiring an additional 498,032 shares during the period. Finally, Point72 Asset Management L.P. increased its holdings in shares of Silence Therapeutics by 219.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock worth $8,505,000 after acquiring an additional 321,300 shares during the period. 98.73% of the stock is currently owned by institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.